Po-Yen Liu
Posters: J Nanomed Nanotechnol
The aim of this study was to investigate the therapeutic efficacy of the combination of lipotecan and 188Re-liposome in Huh-7 xenograft tumor model. The Huh-7 subcutaneous transplantation tumor animal model was established to evaluate the antitumor activity of 188Re-liposome combined with lipotecan (188Re-liposome + lipotecan) treatment compared with monotherapy (188Re-liposome or lipotecan). Mice were administered via intravenous injection with 188Re-liposome (8.65 MBq, 2/5 maximum tolerated dose (MTD), lipotecan (48 mg/kg, 2/5MTD) and normal saline as blank control. To evaluate the targeting and localization of 188Re-liposome in Huh-7 tumor-bearing mice, biodistribution was performed. Tumor growth and body weight were measured to evaluate the antitumor effect. After intravenous administration of 188Reliposome, radioactivity in tumors was 2.03?0.46 %ID/g at 24 h, the tumor/muscle ratios is 6.35?0.88 at 24 h. In the study on therapeutic efficacy, the tumor-bearing mice treated with 188Re-liposome + Lipotecan group showed better mean tumor growth inhibition rate (MGI=0.36, n=6) than those treated with radiotherapeutics of 188Re-liposome (MGI=0.681, n=6) and chemotherapeutics of lipotecan (MGI=0.717, n=6). The synergistic tumor regression effect was observed with the combination index (CI) exceeding 1 (CI=1.356) for combination therapy. These results suggest that lipotecan may be usefully integrated into the 188Re-liposome treatment of Huh-7 tumors, with potential benefits resulting from increased tumor cell radiosensitization to preferential targeting of tumor-associated vasculature.
Po-Yen Liu has completed his PhD at the age of 30 years from China Medical University and postdoctoral studies from Institute of Nuclear Energy Research. He has published more than 9 papers in reputed journals.